Beta-blocker Administration for Cardiomyocyte Division

Status Recruiting

Clinical Trial Summary

Heart failure is a common long-term complication in patients with congenital heart disease (CHD). Medical treatments to promote regeneration of new healthy heart muscle cells have the potential to provide new heart failure treatments for these patients. The development of such therapies is limited by the poor understanding of the ways in which heart muscles grow after birth. Investigators have learned that humans without heart disease generate new heart muscles cells up to the age of 20 years old and that this is decreased in patients with congenital heart disease like Tetralogy of Fallot. Investigators are trying to determine if treatment with a medicine called Propranolol can increase heart muscle cell proliferation and, with that, normalize heart growth. Investigators will examine discarded heart muscle tissue that is obtained during surgery for the presence of new heart muscle cells. Propranolol is approved by the Food and Drug Administration (FDA) to treat a certain kind of benign tumor in infants (hemangioma), but it is not currently approved by the FDA to increase heart muscle growth.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04713657
Study type	Interventional
Source	University of Pittsburgh
Contact	Shannon Janzef, MSN, RN, CBC
Phone	412.692.5760
Email	janzefs@upmc.edu
Status	Recruiting
Phase	Phase 1
Start date	December 16, 2022
Completion date	February 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02534792` - Early Revalvulation After Fallot Repair Improves Clinical Outcome	N/A
Completed	`NCT00536432` - Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot	N/A
Not yet recruiting	`NCT05485545` - Asynchrony in Operated Tetralogy of Fallot	N/A
Completed	`NCT01941576` - Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot	N/A
Active, not recruiting	`NCT03983512` - PULSTA Transcatheter Pulmonary Valve Pre-Approval Study	N/A
Recruiting	`NCT04581668` - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease	N/A
Completed	`NCT01762124` - Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV)	N/A
Active, not recruiting	`NCT02161471` - Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance
Not yet recruiting	`NCT05916976` - Repaired Tetralogy of Fallot: Risc Score From MRI & Clinical Data to Predict the Need for Change of Treatment	N/A
Recruiting	`NCT04106479` - NIRS in Congenital Heart Defects - Correlation With Echocardiography
Completed	`NCT05579964` - The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot	Phase 2/Phase 3
Recruiting	`NCT05236153` - Electroanatomic Interactions Between Transcatheter Pulmonary Valve Prostheses and Anatomic Isthmuses in Repaired Tetralogy of Fallot	N/A
Recruiting	`NCT03049995` - Stress Echo 2020 - The International Stress Echo Study
Completed	`NCT02586740` - Retrospective Review of Anesthetic Considerations for Pulmonary Artery Rehabilitation	N/A
Terminated	`NCT00564993` - Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot	Phase 3
Recruiting	`NCT05122962` - Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
Completed	`NCT06097377` - Lymphatic Magnetic Resonance Imaging Abnormalities in Children With Tetralogy of Fallot: A Case-Control Study
Completed	`NCT03835494` - Analysis of RV-Dysfunction in Fallot Patients	N/A
Not yet recruiting	`NCT03275844` - Physical Capacity and Activity in Children With Congenital Heart Disease	N/A
Recruiting	`NCT02590679` - Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p	Phase 2/Phase 3